12/11
08:21 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/11
08:08 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Needham & Company LLC from a "buy" rating to a "hold" rating.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) was downgraded by analysts at Needham & Company LLC from a "buy" rating to a "hold" rating.
12/9
08:11 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
High
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
12/9
07:00 am
cogt
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Medium
Report
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
12/8
12:00 pm
cogt
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Medium
Report
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
12/4
01:17 pm
cogt
Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
Low
Report
Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? [Yahoo! Finance]
11/14
01:34 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
11/13
08:06 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
11/13
12:45 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
11/12
08:00 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
11/5
09:00 am
cogt
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
High
Report
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
11/4
08:19 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
10/24
08:08 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
10/23
07:00 am
cogt
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
10/20
09:57 am
cogt
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation [Yahoo! Finance]
9/30
10:51 am
cogt
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation [Seeking Alpha]
Low
Report
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation [Seeking Alpha]
9/24
12:02 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Citigroup Inc. from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Citigroup Inc. from $13.00 to $15.00. They now have a "buy" rating on the stock.